Role of PPARα and Its Agonist in Renal Diseases

Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, su...

Full description

Bibliographic Details
Main Authors: Ching-Feng Cheng, Hsi-Hsien Chen, Heng Lin
Format: Article
Language:English
Published: Hindawi Limited 2010-01-01
Series:PPAR Research
Online Access:http://dx.doi.org/10.1155/2010/345098
id doaj-a817d572e3b9455f940eba9f52e6ab35
record_format Article
spelling doaj-a817d572e3b9455f940eba9f52e6ab352020-11-24T20:59:01ZengHindawi LimitedPPAR Research1687-47571687-47652010-01-01201010.1155/2010/345098345098Role of PPARα and Its Agonist in Renal DiseasesChing-Feng Cheng0Hsi-Hsien Chen1Heng Lin2Department of Medical Research, Tzu Chi General Hospital and Department of Pediatrics, Tzu Chi University, Hualien 970, TaiwanGraduate Institute of Clinical Medicine, Taipei Medical University and Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, TaiwanGraduate Institute of Pharmacology and Toxicology, Tzu Chi University, 701 Chung Yang Road, Section 3, Hualien 970, TaiwanPeroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, suggesting that PPARα agonists may be good candidates for treating acute renal failure. In clinical application, PPAR-α activators, such as hypolipidemic drugs in fibric acid class, were proven to have therapeutic effects on metabolic syndrome and cardiovascular disease. This paper focuses on signaling pathways, ligand selectivity, and physio-pathological roles of PPARα in kidney diseases and the therapeutic utility of PPARα modulators in the treatment of diabetes and inflammation-induced nephropathy. Implication of new and more potent PPAR-α activators could provide important insights into the overall benefits of activating PPAR-α clinically for the treatment of dyslipidemia and the prevention of diabetic or inflammation-induced nephropathy in the future.http://dx.doi.org/10.1155/2010/345098
collection DOAJ
language English
format Article
sources DOAJ
author Ching-Feng Cheng
Hsi-Hsien Chen
Heng Lin
spellingShingle Ching-Feng Cheng
Hsi-Hsien Chen
Heng Lin
Role of PPARα and Its Agonist in Renal Diseases
PPAR Research
author_facet Ching-Feng Cheng
Hsi-Hsien Chen
Heng Lin
author_sort Ching-Feng Cheng
title Role of PPARα and Its Agonist in Renal Diseases
title_short Role of PPARα and Its Agonist in Renal Diseases
title_full Role of PPARα and Its Agonist in Renal Diseases
title_fullStr Role of PPARα and Its Agonist in Renal Diseases
title_full_unstemmed Role of PPARα and Its Agonist in Renal Diseases
title_sort role of pparα and its agonist in renal diseases
publisher Hindawi Limited
series PPAR Research
issn 1687-4757
1687-4765
publishDate 2010-01-01
description Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, suggesting that PPARα agonists may be good candidates for treating acute renal failure. In clinical application, PPAR-α activators, such as hypolipidemic drugs in fibric acid class, were proven to have therapeutic effects on metabolic syndrome and cardiovascular disease. This paper focuses on signaling pathways, ligand selectivity, and physio-pathological roles of PPARα in kidney diseases and the therapeutic utility of PPARα modulators in the treatment of diabetes and inflammation-induced nephropathy. Implication of new and more potent PPAR-α activators could provide important insights into the overall benefits of activating PPAR-α clinically for the treatment of dyslipidemia and the prevention of diabetic or inflammation-induced nephropathy in the future.
url http://dx.doi.org/10.1155/2010/345098
work_keys_str_mv AT chingfengcheng roleofpparaanditsagonistinrenaldiseases
AT hsihsienchen roleofpparaanditsagonistinrenaldiseases
AT henglin roleofpparaanditsagonistinrenaldiseases
_version_ 1716784063396708352